134 related articles for article (PubMed ID: 10385078)
1. The evaluation of the safety and tolerability of two formulations of cyclosporine: neoral and sandimmune. A meta-analysis.
Shah MB; Martin JE; Schroeder TJ; First MR
Transplantation; 1999 Jun; 67(11):1411-7. PubMed ID: 10385078
[TBL] [Abstract][Full Text] [Related]
2. Neoral use in the cardiac transplant recipient.
Valantine H
Transplant Proc; 2000 May; 32(3A Suppl):27S-44S. PubMed ID: 10814748
[TBL] [Abstract][Full Text] [Related]
3. Randomized, double-blind, one-year study of the safety and tolerability of cyclosporine microemulsion compared with conventional cyclosporine in renal transplant patients. International Sandimmun Neoral Study Group.
Frei UA; Neumayer HH; Buchholz B; Niese D; Mueller EA
Transplantation; 1998 Jun; 65(11):1455-60. PubMed ID: 9645802
[TBL] [Abstract][Full Text] [Related]
4. Randomized, trough blood cyclosporine concentration-controlled trial to compare the pharmacodynamics of Sandimmune and Neoral in de novo lung transplant recipients.
Trull A; Steel L; Sharples L; Stewart S; Parameshwar J; McNeil K; Wallwork J
Ther Drug Monit; 1999 Feb; 21(1):17-26. PubMed ID: 10051050
[TBL] [Abstract][Full Text] [Related]
5. Experience with neoral versus sandimmune in primary liver transplant recipients.
Pinson CW; Chapman WC; Wright JK; Hunter EB; Awad JA; Raiford DS; Payne JL; Geevarghese S; Blair TK; Van Buren DH
Transpl Int; 1998; 11 Suppl 1():S278-83. PubMed ID: 9664997
[TBL] [Abstract][Full Text] [Related]
6. Cyclosporin microemulsion (Neoral). A pharmacoeconomic review of its use compared with standard cyclosporin in renal and hepatic transplantation.
Coukell AJ; Plosker GL
Pharmacoeconomics; 1998 Dec; 14(6):691-708. PubMed ID: 10346420
[TBL] [Abstract][Full Text] [Related]
7. [A comparative randomized prospective multicenter study of Sandimmune vs Neoral in liver transplantation].
Roy A; Grant DR; Kneteman NM; Tchervenkov JI; Levy GA; Tan A; Hendricks L
Ann Chir; 1998; 52(8):716-21. PubMed ID: 9846420
[TBL] [Abstract][Full Text] [Related]
8. Safety of Neoral conversion in maintenance renal transplant patients: A one-year, double-blind study. NOVARTIS OLN-353 Study Group.
Brennan DC; Barbeito R; Burke J; Brayman K; Greenstein S; Chang T
Kidney Int; 1999 Aug; 56(2):685-91. PubMed ID: 10432409
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients--a concentration-controlled comparison with the commercial formulation.
Mueller EA; Kovarik JM; van Bree JB; Lison AE; Kutz K
Transplantation; 1994 Apr; 57(8):1178-82. PubMed ID: 8178343
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic, hemodynamic, and metabolic effects of cyclosporine sandimmune versus the microemulsion neoral in heart transplant recipients.
White M; Pelletier GB; Tan A; Jesina C; Carrier M
J Heart Lung Transplant; 1997 Aug; 16(8):787-94. PubMed ID: 9286770
[TBL] [Abstract][Full Text] [Related]
11. Comparison of microemulsion and conventional formulations of cyclosporine A in preventing acute rejection in de novo kidney transplant patients. The U.K. Neoral Renal Study Group.
Pollard SG; Lear PA; Ready AR; Moore RH; Johnson RW
Transplantation; 1999 Nov; 68(9):1325-31. PubMed ID: 10573071
[TBL] [Abstract][Full Text] [Related]
12. An open-label study of the safety and tolerability of converting stable liver transplant recipients to neoral.
Pasha TM; Wiesner RH; Dahlke LM; Porayko MK; Krom RA
Liver Transpl Surg; 1998 Sep; 4(5):410-5. PubMed ID: 9724479
[TBL] [Abstract][Full Text] [Related]
13. Neoral compared to Sandimmune is associated with a decrease in histologic severity of rejection in patients undergoing primary liver transplantation.
Graziadei IW; Wiesner RH; Marotta PJ; Porayko MK; Dahlke LJ; Wilson SM; Steers JL; Krom RA
Transplantation; 1997 Sep; 64(5):726-31. PubMed ID: 9311710
[TBL] [Abstract][Full Text] [Related]
14. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun Neoral Study Group.
Keown P; Niese D
Kidney Int; 1998 Sep; 54(3):938-44. PubMed ID: 9734620
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of cyclosporine microemulsion (neoral) versus conventional cyclosporine in liver transplantation: MILTON study. Multicentre International Study in Liver Transplantation of Neoral.
Otto MG; Mayer AD; Clavien PA; Cavallari A; Gunawardena KA; Mueller EA
Transplantation; 1998 Dec; 66(12):1632-40. PubMed ID: 9884251
[TBL] [Abstract][Full Text] [Related]
16. Neoral in de novo liver transplantation: adequate immunosuppression without intravenous cyclosporine.
Levy GA; Rasmussen A; Mayer AD; Jamieson NV; Neuhaus P
Liver Transpl Surg; 1997 Nov; 3(6):571-7. PubMed ID: 9404955
[TBL] [Abstract][Full Text] [Related]
17. Comparison of pharmacokinetics of Neoral and Sandimmune in stable pediatric liver transplant recipients.
van Mourik ID; Thomson M; Kelly DA
Liver Transpl Surg; 1999 Mar; 5(2):107-11. PubMed ID: 10071349
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppressive therapy with microemulsion cyclosporine A shortens the hospitalization of pediatric liver transplant recipients.
Arumugam R; Soriano HE; Scheimann AO; Reid BS; Gopalakrishna GS; Barakat O; Ozaki CF; Wood PR
Clin Transplant; 1998 Dec; 12(6):588-92. PubMed ID: 9850457
[TBL] [Abstract][Full Text] [Related]
19. Safety, tolerability, and efficacy of cyclosporine microemulsion in heart transplant recipients: a randomized, multicenter, double-blind comparison with the oil-based formulation of cyclosporine--results at 24 months after transplantation.
Eisen HJ; Hobbs RE; Davis SF; Carrier M; Mancini DM; Smith A; Valantine H; Ventura H; Mehra M; Vachiery JL; Rayburn BK; Canver CC; Laufer G; Costanzo MR; Copeland J; Dureau G; Frazier OH; Dorent R; Hauptman PJ; Kells C; Masters R; Michaud JL; Paradis I; Renlund DG; Vanhaecke J; Mellein B; Mueller EA
Transplantation; 2001 Jan; 71(1):70-8. PubMed ID: 11211198
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors.
Akhlaghi F; Keogh AM; McLachlan AJ; Kaan A
J Heart Lung Transplant; 2001 Apr; 20(4):431-8. PubMed ID: 11295581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
